![Frontiers | We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database Frontiers | We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database](https://www.frontiersin.org/files/Articles/550201/fpsyt-11-550201-HTML/image_m/fpsyt-11-550201-t001.jpg)
Frontiers | We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database
![Frontiers | Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone Frontiers | Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone](https://www.frontiersin.org/files/Articles/711940/fphar-12-711940-HTML/image_m/fphar-12-711940-g002.jpg)
Frontiers | Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
![Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia | CNS Spectrums | Cambridge Core Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20210331102058022-0286:S1092852918001104:S1092852918001104_fig1g.jpeg?pub-status=live)
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia | CNS Spectrums | Cambridge Core
![Why Does Abilify Cause Compulsive Behaviors? Here is the Answer | Levin Papantonio Rafferty - Personal Injury Law Firm Why Does Abilify Cause Compulsive Behaviors? Here is the Answer | Levin Papantonio Rafferty - Personal Injury Law Firm](https://www.levinlaw.com/sites/default/files/images/abilify-addiction.jpg)
Why Does Abilify Cause Compulsive Behaviors? Here is the Answer | Levin Papantonio Rafferty - Personal Injury Law Firm
![Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial - The Lancet Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/9d562b63-252d-4c61-9f81-c0964f078353/gr1_lrg.gif)
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial - The Lancet
![Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. - Abstract - Europe PMC Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5400404/bin/jcp-37-289-g001.jpg)
Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. - Abstract - Europe PMC
![Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia | CNS Spectrums | Cambridge Core Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20210331102058022-0286:S1092852918001104:S1092852918001104_tab2.gif?pub-status=live)
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia | CNS Spectrums | Cambridge Core
![The European Medicines Agency (EMA) Approves Otsuka's Aripiprazole (ABILIFY®) for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents | New Drug Approvals The European Medicines Agency (EMA) Approves Otsuka's Aripiprazole (ABILIFY®) for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents | New Drug Approvals](http://upload.wikimedia.org/wikipedia/commons/thumb/2/20/Aripiprazole.svg/325px-Aripiprazole.svg.png)
The European Medicines Agency (EMA) Approves Otsuka's Aripiprazole (ABILIFY®) for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents | New Drug Approvals
![Frontiers | Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone Frontiers | Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone](https://www.frontiersin.org/files/MyHome%20Article%20Library/711940/711940_Thumb_400.jpg)
Frontiers | Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
![The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open](https://cyberleninka.org/viewer_images/648279/f/1.png)
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open
![A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia | Psychiatrist.com A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia | Psychiatrist.com](https://www.psychiatrist.com/PublishingImages/14m09741F1.gif)
A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia | Psychiatrist.com
![A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia | Psychiatrist.com A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia | Psychiatrist.com](https://www.psychiatrist.com/PublishingImages/14m09741t2.gif)